Rucaparib (AG-014699) phosphate

目录号:S1098 别名: PF-01367338 中文名称:瑞卡帕布磷酸盐

仅限科研使用

Rucaparib (AG-014699,PF-01367338)是一种PARP抑制剂,无细胞试验中作用于PARP1的Ki为1.4 nM,对其余8个PARP位点也有结合亲和力。Phase 3。

Rucaparib (AG-014699) phosphate Chemical Structure

CAS: 459868-92-9

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 1091.92 现货
RMB 980.68 现货
RMB 1730.04 现货
RMB 5483.69 现货
大包装 有超大折扣

今日订购,明日送达 全国免运费 分装免费 分装成小规格产品(单支最小为1mg)
如1支10mg产品可分装为10支1mg产品

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Rucaparib (AG-014699) phosphate发表文献111篇:

产品安全说明书

PARP抑制剂选择性比较

相关PARP产品

生物活性

产品描述 Rucaparib (AG-014699,PF-01367338)是一种PARP抑制剂,无细胞试验中作用于PARP1的Ki为1.4 nM,对其余8个PARP位点也有结合亲和力。Phase 3。
特性 AG-014699是第一个用于人类癌症疗法的PARP 抑制剂。
靶点
PARP [1]
(Cell-free assay)
1.4 nM(Ki)
体外研究

AG-014699有效抑制纯化的全长人类PARP-1,作用于LoVo和SW620细胞显示出强PARP抑制效果。AG-014699是AG14447的磷酸盐形式,且是第一个和temozolomide联用用于临床实验的PARP抑制剂。[1] AG-014699的辐射增敏性是由于下游NF-κB激活的抑制,及SSB修复抑制。AG-014699可以作用于DNA损伤激活的NF-κB,且克服传统NF-κB抑制剂的毒性,不会损害其他重要的炎症反应。[2]1μM AG-014699作用于D283Med细胞时抑制PARP-1活性达97.1%。[3]在NB-1691, SH-SY-5Y, 和SKNBE(2c)细胞中AG-014699明显增强Topotecan和Temozolomide的细胞毒性。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BT-474 MWnGeY5kfGmxbjDBd5NigQ>? MX6wMlEwOS93MECvNVAxOCCwTR?= MYDpcohq[mm2czDQRXJRKGGldHn2bZR6KGG2IIP0ZZJ1cW6pIHPvcoNmem62cnH0bY9vKG:oIEWwNEBvVQ>? M374blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK4OFU2Lz5{NUGyPFQ2PTxxYU6=
BT474 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPCb2lZPTByIH7N NXLncVdzOTEkgKOxOeKh\A>? MXTy[YR2[2W|IHPlcIwh\3Kxd4ToJIlvKHSqZTDmc5VzKGyrbnXzJIFv\CC|aXfubYZq[2GwdHz5 M{\Cb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK4OFU2Lz5{NUGyPFQ2PTxxYU6=
SKBR3 NHj2fmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlH2OVAxKG6P MV2xNQKBmzF3wrDk M3;HV5Jm\HWlZYOgZ4VtdCCpcn;3eIghcW5idHjlJIZwfXJibHnu[ZMh[W6mIIPp[45q\mmlYX70cJk> NEDo[3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyPFQ2PSd-MkWxNlg1PTV:L3G+
AU565 NIfKVZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnIe2FiPTByIH7N Ml[3NVDjiJNzNdMg[C=> M36xT5Jm\HWlZYOgZ4VtdCCpcn;3eIghcW5idHjlJIZwfXJibHnu[ZMh[W6mIIPp[45q\mmlYX70cJk> MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{OES1OUc,OjVzMki0OVU9N2F-
EFM192A MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHvclVIPTByIH7N NHHDfVIyOOLCk{G1xsBl MnnSdoVlfWOnczDj[YxtKGe{b4f0bEBqdiC2aHWg[o92eiCuaX7ld{BidmRic3nncolncWOjboTsfS=> NF;jZlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyPFQ2PSd-MkWxNlg1PTV:L3G+
MDA-MB-231 NYD6dXU5TnWwY4Tpc44hSXO|YYm= MnrGNVAwOjBxNECg{txO NVLJWWxbOjRiaB?= MoD0bY5kemWjc3XzJJAuSUuWIHzleoVteyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlvyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkCxOVIoRjJ2NEKwNVUzRC:jPh?=
MDA-MB-231 Mn3lR4VtdCCYaXHibYxqfHliQYPzZZk> MnHYNE4yNTRyIN88US=> M1fscVI1KGh? M3fjeWlEPTEkgJm95qCKOTdwN{hCpO69VQ>? MoLLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkCxOVIoRjJ2NEKwNVUzRC:jPh?=
MDA-MB-231 M{e5cmFxd3C2b4Ppd{BCe3OjeR?= M3ntc|ExNzJyL{SwJO69VQ>? MoXhNlQhcA>? NW\2O|BYcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{MEG1Nkc,OjR2MkCxOVI9N2F-
MDA-MB-231 NV7rUnFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnoZlZwOTBxMkCvOFAh|ryP M2f3dVI1KGh? M1Pu[oJtd2OtczDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKGmwIFeyM20heGijc3W= NW\2RlAzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlAyPTJpPkK0OFIxOTV{PD;hQi=>
H460 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDySHM1ODBibl2= NFTPSGEzPMLiaB?= M1jJcYlv[3KnYYPld{Bk\WyudXzhdkBz[WSrb4PlcpNqfGm4aYT5 MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRzMU[xNUc,OjR2MUG2NVE9N2F-
A549  NFLFRpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknaOFAxKG6P NUDIVIcyOjUEoHi= NUfwZ2lRcW6lcnXhd4V{KGOnbHz1cIFzKHKjZHnvd4Vve2m2aY\peJk> Mkn1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MUG2NVEoRjJ2NEGxOlEyRC:jPh?=
DT40 NH;JdnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoW2TWM2OD1{MTDuUS=> MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3NkixN{c,OjR|NU[4NVM9N2F-
DU145 MnjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvkUoZ2UUN3ME2xPEBvVQ>? NFPEfWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO1OlgyOyd-MkSzOVY5OTN:L3G+
COLO704 M3;hT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfYcoUxUUN3ME2yMlUzKMLzIECuOlch|ryP M1jl[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OVMANAb Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfjd4FlUUN3ME2yMlU5KMLzIECuN|gh|ryP M2HxXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OV177 MofiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDMN4VKSzVyPUKuO|ghyrFiMD63NUDPxE1? MknuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
OAW28 NEGwZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDFTWM2OD1|Lk[xJOKyKDBwMkig{txO M3PiXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OVSAHO NHO5VVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXT6bIxlUUN3ME2zMlY1KMLzIECuN|Mh|ryP MlrlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
OVKATE MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLOOlV4UUN3ME2zMlY1KMLzIEGuO|kh|ryP Mm\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
OVCAR3 Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTNwN{SgxtEhOC52MDFOwG0> NGjjSGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
PEO14 NWXK[JMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\IOWlEPTB;Mz64OEDDuSByLke2JO69VQ>? MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
A2780 NVPJ[mtxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn1WlJpUUN3ME2zMlk1KMLzIECuNlUh|ryP NITM[WE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OVTOKO MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fKSmlEPTB;ND6xOEDDuSBzLkWzJO69VQ>? MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
KURAMOCHIb MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUD6VmlbUUN3ME20MlM1KMLzIECuNlkh|ryP NX7MeldXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
TOV21G Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jqZ2lEPTB;NT6wO{DDuSBzLkOwJO69VQ>? NHfVPHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OVISE M3nWbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTVwNkigxtEhOC5{MzFOwG0> MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
KK MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTZwMUWgxtEhOS52MjFOwG0> NVTacm04RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
RMUGS M33PNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPuWGlKSzVyPUeuNFMhyrFiMT64N{DPxE1? MmfYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
PEO6 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4C3V2lEPTB;Nz6wOkDDuSByLke0JO69VQ>? NH7neoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OVCA429 MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7U[Yt4UUN3ME24MlI6KMLzIEGuOlQh|ryP M37Cb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OV167 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUn3TopMUUN3ME24MlM{KMLzIEGuNVgh|ryP MkPDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
RMG1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTlwM{KgxtEhOi5|NjFOwG0> Mn\VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
OVCAR5 NY[xV25nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HJU2lEPTB;OT61NEDDuSB{LkW5JO69VQ>? NF3JVpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
EFO21 NIrJUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvsS4NKSzVyPUmuPVIhyrFiMT64O{DPxE1? MkXGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
ES2 MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXpTWM2OD1zMD6xNkDDuSBzLkKzJO69VQ>? M3;XZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
Tyk-nu MlqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVG1Z|NiUUN3ME2xNE4zOCEEsTCxMlEzKM7:TR?= MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
CAOV3 M{nSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDhRWtuUUN3ME2xNE4{PyEEsTCwMlg4KM7:TR?= M2DiR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OV207 NXzTfIV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHn5UIZKSzVyPUGyMlI4KMLzIECuN|Ih|ryP NVmzZ5NkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
HEY MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml32TWM2OD1zMz6wNUDDuSByLke1JO69VQ>? M{LZXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
DOV13 Mnf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjNeWRKSzVyPkG1JO69VQ>? Ml3pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
EFO27 NYjicXFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;BcIdDUUN3ME6xOUDPxE1? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
HEY C2 M{jvPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vr[GlEPTB-MUWg{txO MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
KOC-7cc Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jObmlEPTB-MUWg{txO MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
MCASb MknvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRjF3IN88US=> M1rxblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OAW42 NUntW4ROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1G5UmlEPTB-MUWg{txO MnfZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
OV2008 NInvcVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWmyOWNCUUN3ME6xOUDPxE1? Mn;NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
OV90 M3\BRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRjF3IN88US=> NHnXNm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OVCA420b M3vSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXBd3dKSzVyPkG1JO69VQ>? MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
OVCA432 NEfCcGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL0TWM2OD5zNTFOwG0> NI[wenI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
PEA2 NU\yNW5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRjF3IN88US=> NVr3WHh6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
SKOV3 NFXOV5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkOwTWM2OD5zNTFOwG0> NH3tfpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
TOV112D NUnCTWF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fmUlAuOyEQvF2= MXvJR|UxRjF3IN88US=> NWSxepo3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
C4-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ewOFAuOyEQvF2= NYfvbWhQOTRiZB?= NFi5RXVFVVOR NWPnT|BE\GWlcnXhd4V{KGOxbH;ufUBvfW2kZYKg[I9{\SCmZYDlcoRmdnSueR?= M1T4VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NU[1NlQ1Lz5{M{W2OVI1PDxxYU6=
PC3 NVywNY5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPQNE0{KM7:TR?= M{CxNFE1KGR? NV;EbFk4TE2VTx?= NV3vTWM1\GWlcnXhd4V{KGOxbH;ufUBvfW2kZYKg[I9{\SCmZYDlcoRmdnSueR?= MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV4NUK0OEc,OjN3NkWyOFQ9N2F-
DU145 MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVWwMVMh|ryP MVGxOEBl MnzsSG1UVw>? MofP[IVkemWjc3XzJINwdG:weTDueY1j\XJiZH;z[UBl\XCnbnTlcpRtgQ>? M17lVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NU[1NlQ1Lz5{M{W2OVI1PDxxYU6=
VCaP  NVjPUmp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLFNE0{KM7:TR?= MlfRNVQh\A>? NI\FO2JFVVOR MlGz[IVkemWjc3XzJINwdG:weTDueY1j\XJiZH;z[UBl\XCnbnTlcpRtgQ>? MnXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NkWyOFQoRjJ|NU[1NlQ1RC:jPh?=
LNCaP  NFP4Z3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYe3dFFqOC1|IN88US=> MmOxNVQh\A>? MnXOSG1UVw>? M4j5NYRm[3KnYYPld{Bkd2yxbomgcpVu[mW{IHTvd4Uh\GWyZX7k[Y51dHl? MkTEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NkWyOFQoRjJ|NU[1NlQ1RC:jPh?=
MDA-MB-468 NFXSUJJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWL4c2pyUUN3ME25Mlch|ryP MlPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4N{ixOlEoRjJ{Nke4NVYyRC:jPh?=
MDA-MB-231 MXHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mkf1TWM2OD1zMzFOwG0> NWDGbIZHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2O|gyPjFpPkKyOlc5OTZzPD;hQi=>
Cal-51 M4jhNGNmdGxiVnnhZoltcXS7IFHzd4F6 NGXMc4ZKSzVyPUiuOkDPxE1? MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ5OEG2NUc,OjJ4N{ixOlE9N2F-
LoVo NHTqR2JHfW6ldHnvckBie3OjeR?= NWPMN5ZMOzBibXnudy=> NI[3R2hKdmirYnn0bY9vKG:oIGDBVnAhcW5iaIXtZY4hVG:YbzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHCxbImoRWRRMS2{aXLvd4UheG:ueX3ldol7[XSrb36g[o9zKDNyIH3pcpMh[nliZnz1c5Jme2OnbnPlJIF{e2G7LDDFR|UxKD1iMD6wNFQ3QSEQvF2u NHr4OYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlcyPyd-Mk[2OVI4OTd:L3G+
MX1 M4fEfWN6fG:2b4jpZ4l1gSCjc4PhfS=> M332N2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KEKUQ1GxMYRm\mmlaXXueEBpfW2jbjDNXFEh[2WubIOsJGVEPTBiPTCwMlAxPTNizszNMi=> MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3MkexO{c,OjZ4NUK3NVc9N2F-
Rosetta2 (DE3) NGPCSoJHfW6ldHnvckBie3OjeR?= MoPBTY5pcWKrdHnvckBw\iCqdX3hckBPNXSncn3pcoFtKD[6aHnzMZRi\2enZDDBVnRFPiBqOEezJJRwKDFzNkGpJIV5eHKnc4Pl[EBqdiCHc3Po[ZJq[2irYTDjc4xqKFKxc3X0eIEzKCiGRUOpJINmdGy|IIXzbY5oKE6DRDugZZMhe3Wkc4TyZZRmKGK7IH\seY9z\XOlZX7j[UBie3OjeTygTWM2OCB;IECuNFE1KM7:TT6= NHrKVIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFc4OCd-MkS5NFA4PzB:L3G+
Rosetta2 (DE3) MUHGeY5kfGmxbjDhd5NigQ>? NULSUo97UW6qaXLpeIlwdiCxZjDoeY1idiB4eHjpd{11[WepZXSgRXJVTDViKEGwN|AhfG9iMUOxO{kh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliUn;z[ZR1[TJiKFTFN{kh[2WubIOgeZNqdmdiTlHEL{BieyC|dXLzeJJifGViYomg[ox2d3Knc3PlcoNmKGG|c3H5MEBKSzVyIE2gNE4xOjVizszNMi=> NFfsW3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFc4OCd-MkS5NFA4PzB:L3G+
LoVo M4jhVmN6fG:2b4jpZ4l1gSCjc4PhfS=> NILMXG8xNjRidV2= NUnoW4kzPSCmYYnz NXG5cHpkWG:2ZX70bYF1cW:wIH;mJJRmdW:8b3zvcYll\S2rbnT1Z4VlKGO7dH;0c5hq[2m2eTDpckBpfW2jbjDMc3ZwKGOnbHzzJIF{e2W|c3XkJIF{KHSnbX;6c4xwdWmmZTDHTVUxKGG2IECuOEB2VSCjZoTldkA2KGSjeYOgZpkhS2WubITpeIVzNUeubzDhd5NigSxiR1m1NEA:KDBwMUS0JO69VS5? MnXnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK3NVcoRjJ4NkWyO|E4RC:jPh?=
Capan1 M2\4SmN6fG:2b4jpZ4l1gSCjc4PhfS=> NYPBXmZzS3m2b4TvfIlkcXS7IHHnZYlve3RiQmLDRVIu\GWoaXPp[Y51KGi3bXHuJGNieGGwMTDj[YxteyxiRVO1NEA:KDBwNkC5JO69VS5? M1L0NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO|E4Lz5{Nk[1NlcyPzxxYU6=
MDA-MB-436 MWrBcpRq[2GwY3XyJIF{e2G7 MmrKPVYhcHK| NXLxV5FNSW62aXPhcoNmeiCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJGJTS0FzLXTl[olkcWWwdDDNSGEuVUJvNEO2JINmdGy|IHHmeIVzKDl4IHjyd{BjgSCPVGSgZZN{[XluIFPDOVAhRSB|IN88UU4> NIS2[5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO0Nlg3QCd-Mk[zOFI5Pjh:L3G+
OVCAR3 MlmxRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M1fnSlI1KGi{cx?= NWj4XmltSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDPWmNCWjNiY3XscJMh[W[2ZYKgNlQhcHK|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFMvOzFizszNMi=> MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR3NkGwOkc,Ojl2NU[xNFY9N2F-
MRC5 NVLGPINFS3m2b4TvfIlkcXS7IHHzd4F6 MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNVmM2KGOnbHzzMEBGSzVyIE2gPE42OyEQvF2u NHHMfIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlcyPyd-Mk[2OVI4OTd:L3G+
MCF7 MmroRY51cWOjbnPldkBie3OjeR?= M4T6Z|k3KGi{cx?= MkXERY51cWOjbnPldkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IF3UWEBie3OjeTygR2M2OCB;IEG5MlQ4KM7:TT6= NV;5UVgxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOFI5PjhpPkK2N|QzQDZ6PD;hQi=>
A673 NH3KZW5yUFSVIHHzd4F6 NUPIflVteUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFG2O|Mh[2WubIO= NWLiR|FURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 NHuzS2pyUFSVIHHzd4F6 NH7MPZNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd|IHPlcIx{MQ>? NFvPVG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh41 M1PvUZFJXFNiYYPzZZk> NHTSRodyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDRzIHPlcIx{ MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC M37XdJFJXFNiYYPzZZk> NULqW5loeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
TC32 NVzienBreUiWUzDhd5NigQ>? M1HoSpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM> MoPSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Assay
Methods Test Index PMID
Western blot BRCA1 PAR 24085845 27960087
Growth inhibition assay Cell viability 31119062
Immunofluorescence 53BP1 γH2AX PAR α-tubulin 23565244 27515310 30589644
体内研究 AG-014699无毒,明显增强D384Med移植瘤DNA修复功能蛋白中temozolomide诱导的TGD。药物动力学研究显示在脑组织中也检测到AG-014699,说明AG-014699用于治疗颅内恶性肿瘤具有潜在可能。[3]活体模型(NB1691和SHSY5Y移植瘤)研究显示AG-014699增强temozolomide的抗癌活性,产生彻底且持久的肿瘤衰退现象。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[3]
  • 激酶实验:

    不同浓度(0到1μ)AG-014699作用于5×103D283Med 细胞,与只用DMSO处理5×103D283Med细胞相比,来测定PARP活性抑制率。参考GCLP验证试验的PAR标准曲线,在和NAD+及寡核苷酸(底物和激活剂)温育的6分钟期间,使用10H PAR抗体,通过PAR形成量的免疫检测,在细胞样本中测量最大程度刺激的PARP活性。

细胞实验: [3]
  • Cell lines: D425Med, D283Med和D384Med细胞
  • Concentrations: 0.4 μM
  • Incubation Time: 3或5天
  • Method: 髓母细胞瘤细胞系包含D425Med, D283Med,和D384Med细胞,分别按1×103, 3×103,和3×103密度接种在96孔板上。接种24小时(D384Med细胞)或48小时(D283Med和D425Med细胞)后,细胞用不同浓度temozolomide处理。培养3天(D425Med和D384Med细胞)或5天(D283Med细胞)后,通过XTT细胞增殖检测试剂盒检测细胞活力。用DMSO处理的对照组和0.4μ AG-014699处理的实验组的百分比表示细胞生长。计算temozolomide单独使用或者和AG-014699联用时的GI50值。Temozolomide单独使用时的GI50值和与AG-014699联用时的GI50值之比就是趋化因子50(PF50)值。
动物实验:[3]
  • Animal Models: 携带D283Med移植瘤的CD-1裸鼠
  • Dosages: 1 mg/kg
  • Administration: 腹腔注射,每天1次或4次

溶解度(25°C)

体外

体内

从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O

10mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 421.36
化学式

C19H18FN3O.H3PO4

CAS号 459868-92-9
储存条件 3年 -20°C 粉状
2年 -80°C 溶于溶剂

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量 浓度 体积 分子量

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04539327 Recruiting Drug: Rucaparib Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer Grupo Español de Investigación en Cáncer de Ovario|Clovis Oncology Inc. July 29 2020 --
NCT04179396 Active not recruiting Drug: Rucaparib|Drug: Enzalutamide|Drug: Abiraterone Metastatic Castration Resistant Prostate Cancer Clovis Oncology Inc. December 5 2019 Phase 1
NCT04171700 Active not recruiting Drug: Rucaparib Solid Tumor Clovis Oncology Inc. November 21 2019 Phase 2
NCT03824704 Terminated Drug: Rucaparib|Drug: Nivolumab Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|High Grade Serous Carcinoma|Endometrioid Adenocarcinoma Clovis Oncology Inc.|Bristol-Myers Squibb|Foundation Medicine August 23 2019 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们
Tags: buy AG-014699|AG-014699 ic50|AG-014699 price|AG-014699 cost|AG-014699 solubility dmso|AG-014699 purchase|AG-014699 manufacturer|AG-014699 research buy|AG-014699 order|AG-014699 mouse|AG-014699 chemical structure|AG-014699 mw|AG-014699 molecular weight|AG-014699 datasheet|AG-014699 supplier|AG-014699 in vitro|AG-014699 cell line|AG-014699 concentration|AG-014699 nmr|AG-014699 in vivo|AG-014699 clinical trial|AG-014699 inhibitor|AG-014699 DNA Damage inhibitor